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Summary  
We studied the efficacy and tolerability of glycosaminoglycan polysulfuric acid (GAGPS) in 80 patients with 
osteoarthritis (OA) of the knee. Patients received two series of five intra-articular injections, at l-week intervals, of 
25 mg (0.5 ml) GAGPS into the knee in a double-blind, parallel, randomized, placebo-controlled trial. There was an 
immediate decrease in pain after the injections of 43% with GAGPS and 33% with placebo (P = 0.047) (Jezek pain 
index). Pain relief of GAGPS vs placebo was not different at other intervals (10, 14, 22, 26 weeks after start of treatment). 
At 6 weeks the Lequesne index decreased 20% after GAGPS and 9% after placebo (P = 0.17). At 10 weeks the Lequesne 
index decreased 24% after GAGPS and 13~/o after placebo (P = 0.20). The decrease in Lequesne index at 14 weeks was 
31% after GAGPS and 15% after placebo (P = 0.06). The other measured parameters tended to be more favorably 
influenced by GAGPS than placebo. GAGPS was well tolerated, with associated mild adverse reactions in 8% of cases. 
GAGPS may have a role as a symptomatic slow acting drug for OA. Further study appears appropriate. 
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Introduct ion 
OSTEOARTHRITIS (OA) of the knee is one of the most 
common diseases of an older population, the 
prevalence being as high as 30% in a population 
~>63 years of age [1]. Disturbed metabolism of 
the carti lage is important at the onset of OA 
and throughout its progression. The natural  
equilibrium between the synthesis of the carti lage 
extracel lular matrix and its enzymatic degradation 
is disturbed, resulting in loss of matrix. This loss 
in hyaline cartilage matrix alters the unique 
biochemical characterist ics necessary for normal 
art icular function [2, 3]. 
In in vitro studies, glycosaminoglycan polysulfu- 
ric acid (GAGPS) (Arteparon ~, Luitpold Pharma) 
inhibited the action of different hydrolases, 
glycosidases, and proteases (e.g. cathepsin B1 and 
elastase) involved in the degradation of the matrix 
[4-7]. In animal models of OA, similar inhibitory 
effects were demonstrated on metalloproteinases 
and serine proteinases [8]. GAGPS has also shown 
an anabolic action on chondrocytes. Kleesiek and 
Greiling [9] demonstrated direct stimulation of 
proteoglycan synthesis by chondrocytes. Adam 
et al. [10] showed GAGPS stimulation of collagen 
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synthesis by chondrocytes. One study showed that 
GAGPS stimulated an increase in synovial fluid 
viscosity, related to an increase in the amount of 
hyaluronate [11]. GAGPS seems to preserve the 
anatomy of carti lage in animal models of OA both 
by macroscopic examination and histology [12]. 
GAGPS has been studied in numerous clinical 
trials for the last 25 years. GAGPS was shown to 
be superior to placebo in a short-term (16-weeks) 
double-blinded study [13]. It was also of clinical 
benefit in a long-term (5-year) open study in knee 
OA by Rejholec and Kr~lov~ [14], where the X-ray 
progression of diseases was retarded. In a double- 
blind, 3-year study of hand OA, GAGPS seemed to 
prevent he formation of OA in initially normal- 
appearing joints; however, it did not retard the 
progression of disease in interphalangeal joints 
that already had OA at the beginning of the study 
[15]. 
GAGPS is structural ly similar to heparin. Local 
hematomas are sometimes observed. Changes of 
systemic coagulation parameters are not demon- 
strated at a dose of 50 mg intra-articularly (i.a.). 
Also, systemic adverse drug reactions have been 
described (atlergically-induced disorders of 
platelet function with shock symptoms and 
tendency toward bleeding and/or thrombosis and 
reversible hair loss). As these adverse drug 
reactions seem to be dose-related, we concluded 
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that a clinical trial should be carried out with a 
reduced dose of GAGPS (25 mg instead of 50 rag). 
Mater ia l s  and  methods  
The study was a l-year double-blind, randomized, 
placebo-controlled parallel-group study of 80 
patients with OA of the knee. Normal saline was 
used as the placebo. The therapeutic unit 
contained 2 × 5 ampules, 0.5 ml each, containing 
either 25 mg GAGPS or normal saline. It was 
impossible to distinguish the ampules or the pack- 
aging of the GAGPS-containing therapeutic units 
from those that contained placebo; they were ident- 
ified only by their randomization numbers. • 
CRITERIA  FOR INCLUSION INTO THE STUDY 
Age of 40-75 years, and a diagnosis of 
symptomatic knee OA defined in accordance with 
the ACR criteria [16]. Duration of disease, height, 
weight, employment s atus, laterality of the more 
symptomatic knee, and baseline consumption of 
nonsteroidal anti-inflammatory drugs were 
determined at enrolment. In addition, patients 
underwent radiographic examination of both 
knees. 
EXCLUSION CRITERIA  
These included the following: allergy to GAGPS 
or to heparin and heparinoids; a history of throm- 
boembolic disease, hypertension, or coagulation 
disturbances; concomitant herapy with drugs 
known to effect blood coagulation or platelet 
function; type I diabetes; history of peptic or 
intestinal ulcer disease; hepatic, renal, or pancre- 
atic insufficiency; and serious ischemic heart 
disease. Inflammatory articular diseases, synovial 
chondromatosis, chondrocalcinosis, gout and 
psoriasis; joint effusions of greater than 25 ml; 
obesity beyond 30% of ideal body mass, 
pronounced genua vara or valga; hip OA and prior 
lower extremity total joint replacement; prior 
intra-articular dministration of corticosteroids or
chondroprotective drugs within 3 months; infec- 
tious diseases, fever; skin disease at the site of 
administration; pregnancy and nursing; general 
contraindications to oral ibuprofen; rheumatoid 
factor of above 1:40, erythrocyte sedimentation 
rate (ESR) of above 40 mm/h, uric acid of above 
500 umol/1, and platelet count less than 
130,000/mm 3. 
THE THERAPY 
The patients received five injections of GAGPS 
into the more symptomatic knee joint at l-week 
intervals at a dose of 25 mg (i.e. one-half of the 
commercial GAGPS dose at doubled injection in- 
tervals). The intra-articular injections were 
administered by a blinded physician after clinical 
examination. Six patients had started a second 
injection cycle and had received one or more 
additional injections. Both GAGPS and saline 
were in identical vials. 
THE CONCOMITANT THERAPY 
Ibuprofen tablets (400mg) administered on 
demand up to six tablets  daily, consumption 
monitored as one of the criteria of efficacy. Other 
analgesics and intra-articular steroids were not 
permitted. 
INTERVALS OF  ASSESSMENT 
Before the initiation of therapy and during treat- 
ment at l-week intervals (weeks 1~6), and then at 
l-month intervals (weeks 10, 14, 18,~21, 26). 
Primary efficacy parameter 
The primary efficacy parameter was the 
Lequesne index of severity for the knee (ISK) [17]. 
The reference joint was the injected knee. 
Secondary efficacy parameters 
Pain score according to Jegek [18]. This evalu- 
ated seven pain qualities within a four-point scale 
(0: no pain, 1: slight pain, 2: medium pain, 3: severe 
pain, 4: unbearable pain): at the onset of walking, 
pain during walking, pain when walking down- 
stairs and upstairs, pain during the night, pain 
during maximal flexion, and pain upon palpation. 
The maximum score was 28. 
The visual analog scale. This was for measuring 
average global pain during the previous week--a 
horizontal scale, 100 mm, without dividing marks, 
measured in mm. 
Functional test. This was the time in seconds to 
walk a distance of 20 m as fast as possible on an 
even surface. 
Physical examination. This involved looking for 
any tenderness, welling, effusion, elevated skin 
temperature at the knee joint, extent of mobility, 
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Table I 
Characteristics of the patients 
Arteparon Placebo Significance 
Men : women 10 : 25 8 : 28 NS 
Age (year) 62.7 __+ 5.9 62.7 ± 8.3 NS 
Weight (kg) 75.0 +__ 10.4 76.3 _+ 10.9 NS 
Height (cm) 167 _ 9 168 ± 8 NS 
Employed:unemployed 27 : 8 25 : 11 NS 
Lequesne index 9.8 ± 3.6 9.4 + 3.4 NS 
Duration of symptoms:N(%) 
< 1 year 1 (3) 2 (6) NS 
1-2 years 4 (11) 6 (17) NS 
2-5 years 12 (34) 10 (28) NS 
> 5 years 18 (51) 18 (50) NS 
crepitus, and pain  on pass ive mot ion  (none present,  
sl ight, moderate,  severe). 
ur ic acid, a lka l ine  phosphatase,  AST, ALT,  and 
GGTP.  
Global assessment of the efficacy and tolerability 
of the therapy according to the physician and 
patient. This had four degrees: poor, moderate,  
good, very good. 
Ibuprofen consumption in the course of the 
therapy. Number  of 400 mg taken,  with a max imum 
of 6 tablets  daily. 
Pat ients  were quest ioned careful ly  for adverse 
events. None were suggested to the pat ients.  All 
adverse events were recorded, even those thought  
not  to be drug-related. 
LABORATORY F INDINGS 
Laboratory  studies were determined at basel ine, 
and at 6 and 26 weeks. The fol lowing laboratory  
invest igat ions -were  performed: ESR, C react ive 
protein,  complete blood count  ( including platelet  
count  and differential),  serum potassium, sodium, 
glucose, blood, urea ni trogen,  creat in ine,  bi l irubin, 
STATIST ICS  
Stat ist ica l  eva luat ion  was carr ied out  in the 
B iometr ics  Depar tment  of the sponsor.  Conf irma- 
tory  analys is  was based on test ing for group 
dif ferences upon the main  parameter  (the ISK  
score) at weeks 14, 18 and 22 by mul t ivar ia te  
T<test ,  fol lowed by un ivar ia te  t-tests at  a mul- 
t iple level of ~ =5% (closed test  pr inciple).  
Analys is  on secondary  parameters  (t-test, 
Wi lcoxon test) were done in an exp lora tory  
sense. Thus P -va lues  reported are to be inter- 
preted in the sense of stat ist ical  ev idence for 
group differences. 
Sample size ca lcu lat ion was based on the 
fol lowing assumptions:  type I error  p robab i l i ty  
= 5%, type I I  e r ror  probabi l i ty  fl = 10%, stan- 
dardized dif ference for ma in  parameter  ISK  
score = 0.75. Thus 40 pat ients  per group would be 
necessary  to get s ignif icant stat ist ica l  resul ts  
(based on two-sided t-test). 
Randomizat ion  was based on a code produced by 
Table II 
Characteristics of the patients: location and radiographic involvement 
Arteparon Placebo 
N .~% N % Significance 
OA involvement: 
right 5 (14) 5 (14) NS 
left 6 (17) 5 (14) NS 
bilateral 24 (69) 26 (72) NS 
Knee treated: 
right 15 (43) 19 (53) NS 
left 20 (57) 17 .  (47) NS 
Medial joint space narrowing 27 (77) 30 (83) NS 
Lateral joint space narrowing 10 (29) 14 (39) NS 
Patellofemoral OA 16 (46) I9 (53) NS 
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Table III 
ISK results (Lequesne index) 
GAGPS points Percentage Placebo points Percentage 
Weeks ( +_ S.D.) change ( _+ S.D.) change P-value* 
0 9.8 + 3.6 9.4 + 3.4 0.64 
6 7.7 ± 3.5 -19.7 8.2+_3.2 -8.6 0.17 
10 7.5 _+ 4.1 - 23.9 7.9 ± 3.4 - 13.0 0.20 
14 6.9 + 4.4 - 30.9 7.8___ 3.6 - 14.7 0.06 
18 7.4 + 4.4 - 26.5 7.4 ± 3.6 - 18.6 0.35 
22 7.7 _+ 4.6 - 23.9 7.4 ± 4.1 - 20.6 0.71 
26 7.7 ± 4.7 - 23.5 7.7 ± 4.5 - 19.5 0.66 
*Two-sided Student's t-test. 
a random number generator  (Proc Plan, SAS (K)) 
according to chronological  entry to the study. 
Resu l ts  
THE HOMOGENEITY  OF  THE GROUPS TREATED 
Nine patients were el iminated in the statist ical 
evaluat ion of the study, hav ing not fulfilled the 
condit ions of the protocol.  Five were subsequently 
determined to be over the weight limit, two had 
taken other therapy excluded by the criteria of the 
study, and two did not appear for cl inical follow- 
up. Thus, a total  of 71 patients were evaluated: 
GAGPS 36; saline 35. There were no differences 
between the groups in any of the pat ient character-  
istics at enrol lment noted in Methods, the degree 
of jo int space narrowing medial ly and laterally, 
the baseline severity of the disease according to 
the Lequesne index [19], and the basel ine consump- 
t ion of nonsteroid ant i - inf lammatory drugs 
(Tables I & II). 
All patients were in stage II or I i I  according to 
Kel lgren-Lawrence [20]. All pat ient were ambulat- 
ory. None had flexion contractures  of the knees. 
Evidence of inf lammation was present in the knees 
of some patients, but the presence of a large 
effusion was an exclusion criterion. Pat ients  with 
concomitant  hip OA were excluded from the study, 
but some had hand OA. 
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Fro. 1. Index of severity of knee OA as reported subjectively by patients, plotted as percentage change from baseline 
vs time. Vertical bars indicate I S.D. GAGPS was not statistically significant vs saline at any time point. (- ) GAGPS; 
( - - - )  saline. 
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Table IV 
Visual analogue scale (mm )
GAGPs points Percentage Placebo points Percentage 
Weeks ( _+ S.D.) change ( _+ S.D.) change P-value* 
0 44.8 __+ 19.2 41.7 __+ 18.3 0.41 
6 27.8 __+ 20.9 - 34 27.5 __+ 18.7 - 24 0.53 
10 25.8 + 22.7 - 40 28.2 +__ 21.4 - 25 0.32 
14 23.4 +__ 22.3 - 47 26.6 __+ 23.2 - 34 0.28 
18 24.8 __+ 23.9 - 43 25.7 __+ 23.5 - 37 0.64 
22 26.2 + 24.7 -42  27.2 __+ 23.6 -31  0.40 
26 26.2 +__ 24.0 - 39 28.4 __+ 25.7 - 29 0.44 
*Two-sided Student's t-test. 
INDEX OF SEVERITY FOR THE KNEE ( ISK- -LEQUESNE) 
Th is  decreased  a f te r  therapy  w i th  i .a. GAGPS as 
we l l  as  a f te r  i .a. sa l ine  when compared  to base l ine .  
The  lowest  va lues  were  ach ieved  for  GAGPS at  14 
weeks .  S ign i f i cant  improvement ,  however ,  pers i s ted  
for the  ent i re  per iod  of  fo l low-up  (26 weeks)  a f te r  
i .a. GAGPS as we l l  as  i .a. sa l ine  therapy  w i th  no  
s ign i f i cant  d i f fe rences  between the  two.  The  re la t ive  
percent i le  changes  in  the  s tudy  parameters  be- 
tween GAGPS and sa l ine  therapy  approached sig- 
n i f i cance  at  14 weeks  (P  = 0.06). (Tab le  I I I ;  F ig .  1). 
A ca lcu la t ionbased  on the  s tudy  resu l ts  ( t reatment  
d i f fe rence  ISK  at  week  14: 16%; es t imated  s tandard  
dev ia t ion :  36%) showed that  the  ac tua l  power  of  the  
s tudy  for  s ta t i s t i ca l ly  ver i fy ing  th i s  d i f fe rence  was  
on ly  47% and thus  be low the  ant ic ipated  90%. 
VISUAL ANALOG PAIN SCALE 
The  resu l ts  a f te r  GAGPS were  bet ter  than  those  
a f te r  sa l ine  but  the  d i f fe rences  were  not  s igni f i -  
cant  a t  a l l  assessment  po in ts  (Tab le  IV; F ig .  2). 
JEZEK'S PAIN INDEX 
There  was  a decrease  in th is  index  a f te r  
therapy  w i th  GAGPS as we l l  as  sa l ine .  A t  6 
weeks  the  d i f fe rence  between GAGPS and 
sa l ine  was  bare ly  s ign i f i cant  (P  = 0.047) (Tab le  V; 
F ig .  3). 
There  was  no change in the  20 m wa lk ing  t ime 
and  no d i f fe rences  were  observed  between GAGPS 
and sa l ine .  
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Fro. 2. Relat ive change in the visual analog scale shown as percentage change vs time. Vert ical  bars indicate 1 S.D. 
GAGPS was not stat ist ica l ly  signif icant vs sal ine at any time point. ( ) GAGPS; ( - - - )  saline. 
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Table V 
Jegek pain score 
GAGPS points Percentage Placebo points Percentage 
Weeks ( ± S.D.) change ( ± S.D.) change P-value* 
0 11.1 ± 3.7 10.9 ± 4.1 0.89 
6 6.3 ± 3.9 - 43 7.3 ± 3.1 - 33 0.047 
10 6.1 ±4.5 -45  7.1 ± 3.9 -35  0.16 
14 6.3 ± 4.9 - 43 6.8 ± 4.3 - 37 0.46 
18 6.7 ± 5.2 - 40 6.3 __ 3.9 - 42 0.87 
22 6.7 + 5.3 - 40 6.4 + 4.6 - 41 0.97 
26 6.5 ± 5.3 - 41 6.4 ± 4.6 - 41 0.97 
*Wilcoxon test. 
IBUPROFEN CONSUMPTION 
Af ter  10 weeks  of  therapy  th i s  was  reduced a f te r  
GAGPS as wel l  as sa l ine .  Before  therapy  w i th  
GAGPS,  80% of  pat ients  used  three  tab le ts  or  more  
da i ly ;  a f te r  10 weeks ,  th i s  reduced to on ly  43°//0 of  
pat ients .  In  the  i.a. sa l ine  therapy  group,  ibupro fen  
consumpt ion  was  83°//0 at  base l ine  and  47%/o at  10 
weeks .  There  was  no d i f fe rence  between GAGPS 
and sa l ine - t reated  groups .  
PHYSICIANS' GLOBAL ASSESSMENT 
Immediate ly  a f te r  therapy  (6th week) ,  more  'very  
good '  resu l t s  were  observed  a f te r  GAGPS (43%) 
than  a f ter  sa l ine  (17%) (F ig.  4), suggest ing  a thera -  
peut ic  benef i t  o f  GAGPS.  However ,  when combin -  
ing  'very  good '  and  'good '  resu l t s ,  the  d i f fe rence  
between them is not  s ign i f i cant  (P  =0.08) .  
Subsequent  eva luat ions  between GAGPS and 
sa l ine  groups  were  essent ia l l y  the  same.  
PATIENTS' ASSESSMENT OF TREATMENT EFFICACY 
S imi la r ly  immediate ly  a f te r  therapy  in the  
GAGPS group t reatment  eff icacy was  ra ted  as 'very  
good '  in  49~/o of  cases  25% in the  p lacebo  group  
(F ig.  5). These  resu l ts  were  not  s ta t i s t i ca l ly  dif fer-  
ent  (P  = 0.18). The  subsequent  eva luat ions  were  
the  same as that  of  the  phys ic ian 's  eva luat ion .  
A t  the  6 month  eva luat ion ,  compla in ts  had  com- 
p le te ly  d i sappeared  in th ree  pat ients  a f te r  GAGPS 
and  in  one pat ient  a f te r  sa l ine  p lacebo  t reatment .  
A l lev ia t ion  of  symptoms was  st i l l  p resent  in 80~/o 
t reated  w i th  GAGPS and  72~/o w i th  sa l ine .  
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Fro. 3. Relative change in Je~ek's pain index shown as percentage change vs time. Vert ical  bars indicate 1 S.D. GAGPS 
was signif icantly better than sal ine at week  6. 
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FIG. 4. Physicians' characterizations of the results of the blinded therapy as 'very good', 'good', 'moderate' or 'bad'. 
There were no statistically significant differences between GAGPS and saline. [~: GAGPS; []: saline. 
All analysis is based on the intent to treat 
principle (all randomized patients gave similar 
results). 
with placebo, 83% reported to lerance as very good 
and 17% as good; no pat ient reported it as poor. 
The differences were not stat ist ical ly signif icant. 
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In the group treated with Arteparon, 89°//0 of 
pat ients reported the to lerance as very good, 5.7% 
as good and 5.7% as moderate. In the group treated 
ADVERSE EVENTS 
These occurred in four of 80 pat ients (all 
randomized patients). One woman reported pains 
th roughout  the body after placebo inject ion which 
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FIG. 5. Patients' characterizations of the results of the blinded therapy as 'very good', 'good', 'moderate' or 'bad'. There 
were no statistically significant differences between GAGPS and saline. [~: GAGPS; []: saline. 
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Table VI 
Adverse effects 
Time after Order number 
Group Event injection of injection Duration 
GAGPS Bleeding from 0 3 7 min 
the site of injection 
GAGPS Articular exudate 3 h 7* 1-2 days 
Placebo Arthralgia and hot flashes 5 days 5 1 day 
throughout the body 
GAGPS Pain after injection 0 2 1 day 
*Six patients received a second series of injections. 
disappeared in 24 h. The remaining adverse vents 
occurred in association with GAGPS adminis- 
tration: in one man, bleeding was observed for 
7min from the site of injection after i.a. GAGPS ~" 
administration; o bleeding occurred after further 
injections. In another man, there was an effusion 
2 days after GAGPS injection, which disappeared 
two days later, permitting the continuation of 
therapy. One woman felt local pain after GAGPS 
injection, which disappeared within 24h. These 
trivial complications, probably attributable to 
GAGPS injection, represented 7.5% of the cases 
and they never esulted in interrupting the therapy 
(Table VI). 
Discuss ion  
Interpretation of the results of the study is 
problematic. Injection of 5 x 25mg GAGPS into 
the knee joint was statistically different from 
saline only at week 6 of the 26-week study 
(measured on the Pain index). The Lequesne Index 
tended toward a difference favoring GAGPS 
(P=0.06)  at week 10. The other measured 
parameters (pain on VAS, morning stiffness, global 
assessment by patient and physician) also favored 
GAGPS but not to the level of statistical signifi- 
cance. From the standpoint of the biologist-phys- 
ician, however, further interpretations may be 
made. The decrease in pain after GAGPS is 
considerable, almost as much as 50% of the initial 
values. A total of almost 50% considered the re- 
sults of the therapy as very good (week 6). The 
differences when compared to placebo are at the 
limit of significance (P = 0.08). It is, however, 
known that the placebo effect of i.a. injections is 
rather high. In addition, in this case, we have a 
so-called untrue placebo effect, since the adminis- 
tration of any physiologic fluid alleviates pain. It 
is suggested this is due to the dilution of the 
enzymatic systems and inflammatory mediators 
present in the joint. 
Ibuprofen consumption decreased rapidly in 
both groups, with no significant changes between 
GAGPS and saline. This reflects variabil ity of the 
disease and its therapeutic responses as well as the 
need for controlled trials. 
Although GAGPS was not statistically different 
from placebo in most measures:in this double-blind, 
placebo-controlled trial, a potential role for 
GAGPS as a symptomatic drug for OA may still 
exist. 
The present study was initiated in 1991. Its 
original duration was to be 12 months with two 
courses of i.a. GAGPS. In the course of the study 
the manufacturer placed a stop to further GAGPS 
administration, so that the second series of injec- 
tions was not performed. Nevertheless the first half  
of the study (6 months) was carried out in accord- 
ance with the protocol reported above. 
In future we suggest that trials of GAGPS should 
include: (1) 50mg and 25mg i.a. GAGPS in two 
treatment courses of 5-10 injections each, given 
within one year, to establish a 'minimal effective 
dose' and toxicity profile; (2) a double-blind 
comparison study of GAGPS and other disease 
modifying OA drugs; (3) the use of some newer 
objective measures of response, such as magnetic 
resonance imaging or ultrasound. 
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